Category: clinical study retractions

Cancer researcher logs 6 retractions, bringing total to 10

Anil Jaiswal

A journal has retracted six papers by a cancer researcher at the University of Maryland in Baltimore, bringing his total to 10.

The retractions cite an investigation by the university, and detail problems ranging from duplicated images, to tweaking an image to conceal particular bands, to including unreliable data.

Three of the papers had already been flagged by the journal with expressions of concern. The last author on all the papers is Anil Jaiswal, a professor in the pharmacology department. He has issued four previous retractions.

Bruce Jarrell, the Chief Academic and Research Officer and Senior Vice President at the University of Maryland, told us at least two more retractions are forthcoming:

Continue reading Cancer researcher logs 6 retractions, bringing total to 10

Columbia University probe prompts retraction of cardiovascular paper

A journal has retracted a 2011 study at the request of Columbia University.

According to Jeanine D’Armiento, the study’s last author, the newly retracted paper in Clinical Science contained a figure from a Journal of Hypertension paper published by the same authors earlier that year. 

First and corresponding author Joseph George told Retraction Watch the error was unintentional. A Columbia spokesperson sent us this statement: Continue reading Columbia University probe prompts retraction of cardiovascular paper

Backlash prompts prominent nutrition researcher to reanalyze multiple papers

Brian Wansink

To Brian Wansink of Cornell University, a blog post he wrote in November, 2016, was a meant as a lesson in productivity: A graduate student who was willing to embrace every research opportunity submitted five papers within six months of arriving to his lab, while a postdoc who declined two chances to analyze a data set left after one year with a small fraction of the grad student’s publications.

But two months and nearly 50 comments on the post later, Wansink — known for so much high-profile nutrition research he’s been dubbed the “Sherlock Holmes of food” — has announced he’s now reanalyzing the data in the papers, and will correct any issues that arise. In the meantime, he had to decline requests to share his raw data, citing its proprietary nature.

As Wansink writes in the second addendum to the November blog post, “The Grad Student Who Never Said ‘No’:”

Continue reading Backlash prompts prominent nutrition researcher to reanalyze multiple papers

Study of child with rare cancer retracted due to lack of parental consent

Researchers in Ireland have retracted a case study about a rare type of cancer in a child because – contrary to what they claimed in the paper – they had not obtained the necessary permission from the parents.

In the June 2016 article, the authors stated they had received “written informed consent” from the parents to publish the case. But according to the retraction notice — issued just a few months later in October — that was not the case.

Here’s the retraction notice for “Paediatric Ewing-like sarcoma arising from the cranium – a unique diagnostic challenge,” which for legal reasons, the publisher has withdrawn from public view:

Continue reading Study of child with rare cancer retracted due to lack of parental consent

Dangerous chemo mistake retracted by journal after two years

An oncology journal has retracted a 2014 paper that contained a potentially fatal mistake.

Specifically, the paper suggested that a chemotherapy drug be injected intrathecally — i.e., in the spine. But according to the retraction notice, the medical literature has unequivocally shown that that form of treatment is “uniformly fatal.”

The retraction comes approximately 18 months after the journal published a letter to the editor alerting readers to the risky wording in the 2014 paper.

Here’s the notice, issued by Hematological Oncology:

Continue reading Dangerous chemo mistake retracted by journal after two years

Prominent Harvard researcher issues second retraction, again citing duplication

The former president of the Joslin Diabetes Center has withdrawn a second article within a month of his first, and issued extensive corrections to another paper in the same journal, all due to figure errors.

In November, we reported that Carl Ronald Kahn — also affiliated with Harvard Medical School — had pulled a highly cited 2005 paper from The Journal of Clinical Investigation because of image duplication issues, which Kahn told us were introduced during figure assembly. This December, Kahn retracted a 2003 paper published in The Journal of Biological Chemistry (JBC)—again due to duplication issues that the authors believe “were inadvertently introduced during figure assembly.”

Here’s the retraction notice for “Bi-directional regulation of brown fat adipogenesis by the insulin receptor,” cited 46 times, according to Clarivate Analytics’ Web of Science, formerly part of Thomson Reuters:

Continue reading Prominent Harvard researcher issues second retraction, again citing duplication

“Boom, headshot!” Disputed video game paper retracted

After a years-long dispute over a 2012 paper which suggested there might be some effects of first-person shooter video games on players, the journal has retracted the paper.

The stated reason in the notice: Some outside researchers spotted irregularities in the data, and contacted the corresponding author’s institution, Ohio State University, in 2015. Since the original data were missing, Communication Research is retracting the paper, with the corresponding author’s okay.

But as our story last month about this years-long dispute reported, there is a bit more to it.  Continue reading “Boom, headshot!” Disputed video game paper retracted

Undisclosed conflicts of interest usually lead to corrections – but for some journals, that’s not enough

When authors are faced with filling out a journal’s conflict of interest form, deciding what qualifies as a relevant conflict can be tricky. When such omissions come to light, only rarely do they result in retractions – and certainly not author bans. But there are exceptions.

In October, the journal Chest retracted a 2015 review article exploring how mechanical ventilation can be used most effectively to manage acute respiratory distress syndrome (ARDS) after finding that the authors failed “to disclose all relevant conflicts of interest.” What’s more, the journal initially planned to ban the two authors with undisclosed conflicts from submitting papers to the journal for three years, but ultimately decided against it.

The Committee on Publication Ethics says that retractions may be warranted in cases of undisclosed conflicts of interest, but in our experience, most notices that cite that reason mention other problems with the paper, as well. Not this case – here, the only thing that seemed wrong with the paper was the authors’ failure to mention their ties to a ventilator company. The authors requested a correction – the usual fix, one accepted by the other journals they contacted – but to Chest, that wasn’t enough.

Here’s the retraction notice for “Mechanical Ventilation as a Therapeutic Tool to Reduce ARDS Incidence”: Continue reading Undisclosed conflicts of interest usually lead to corrections – but for some journals, that’s not enough

A Harvard whistleblower was subjected to a forced mental exam. Here’s why.

Last March, a PhD student at Harvard filed a misconduct allegation against his mentor, a prominent stem cell researcher. Three months later, he was taken from his home by police in the middle of the night for a forced psychiatric evaluation.

How did this happen? Continue reading A Harvard whistleblower was subjected to a forced mental exam. Here’s why.

Breast cancer studies by fired Pfizer employee retracted

Last year, Pfizer fired one of its scientists following an investigation that ended with requests for retraction of five of her studies. Now, two of the five papers, which were first flagged on PubPeer, have been retracted.

One notice cites the Pfizer investigation, which found that cancer researcher Min-Jean Yin had included duplicated images in all five papers. Yin is the last author on both retracted papers.

Here’s the first notice from Clinical Cancer Research, which says most or all of the questioned images appear to be duplicates, and Pfizer — who sponsored the study and requested the retraction — can’t find the originals:
Continue reading Breast cancer studies by fired Pfizer employee retracted